Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges

Diabetes Care

Volumn 37, Issue 1, 2014, Pages 210-216

  Ghazi, Tara ^a   Rink, Linda ^a   Sherr, Jennifer L ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PARACETAMOL; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON SUPPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HORMONE RESPONSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; ADOLESCENT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 84892423658     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1169     Document Type: Article

References (30)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987;2:1300-1304
2. Ahŕen B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:473-478
3. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulindependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
4. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635
5. Madsbad S, Schmitz O, RanstamJ, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after oncedaily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-1342
6. Solis-Herrera C, Triplitt C, Garduno-Garcia JJ, Adams J, DeFronzo RA, Cersosimo E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: A double-tracer study. Diabetes Care 2013;36:2756-2762
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55: 1577-1596
8. Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: Time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care 2008;31: 1403-1404
9. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143: 4397-4408
10. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-5158
11. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores b-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52:1786-1791
12. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
13. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433
14. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
15. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34:1463-1468
16. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006;55:3238-3245
17. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on b-cell function in long-standing type 1 diabetes. Diabetes Care 2009;32:2251-2257
18. Kielgast U, Holst JJ,Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-cell function. Diabetes 2011;60:1599-1607
19. ibridge. Chronobiological Series Analyzer (CSA) [article online], 2013. Available from http://www.ibridgenetwork.org/uctech/chronobiological-series- analyzer-csa. Accessed 14 August 2013
20. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B. Use of biosynthetic human c-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 1986; 77:98-105
21. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41: 368-377
22. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84
23. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33:1294-1296
24. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996;19:580-586
25. Dupŕe J, BehmeMT,McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-3473
26. Waget A, Cabou C, Masseboeuf M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2011;152:3018-3029
27. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-2713
28. Gutniak M, Orskov C, Holst JJ, Ahŕen B, Efendíc S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-1322
29. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: Role of GLP-1 analogs. J Investig Med 2013; 61:40-44
30. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007; 148:5136-5144